



Curriculum Vitae

Personal information **Massimo Siciliano**

Work experience

1. Employer: Ospedale Fatebenefratelli Gemelli Isola
 - Start date: 092022
 - End date: 092023
 - Position: Director, Internal Medicine and Gastroenterology Unit
 - Activities:
 - Country: Italy
2. Employer: Policlinico Gemelli Foundation _ Catholic University of the Sacred Heart, Roma
 - Start date: 012022
 - End date: 092022
 - Position: Senior Consultant, Internal Medicine and Gastroenterology
 - Activities: Hepatologist and gastroenterologist. Diagnosis, treatment and follow_up of patients with acute and chronic viral hepatitis, autoimmune hepatitis, complications of advanced liver disease, hepatocellular carcinoma, acute and chronic pancreatitis, inflammatory bowel disease and other acute and chronic bowel diseases, and acute and chronic biliary diseases in a large teaching hospital. These activities have been executed for inpatients with acute diseases of the gastrointestinal tract coming from the emergency department and in outpatients facilities.
 - Country: Italy
3. Employer: Regina Apostolorum Hospital – Albano Laziale _Roma (Italy)
 - Start date: 012019
 - End date: 122021
 - Position: Director, Gastroenterology and Hepatology Unit
 - Activities:
 - Country: Italy
4. Employer: Policlinico Gemelli Foundation _ Catholic University of the Sacred Heart, Roma
 - Start date: 072015
 - End date: 122017
 - Position: Consultant, Internal Medicine and Gastroenterology
 - Activities: Hepatologist and gastroenterologist. Diagnosis, treatment and follow_up of patients with acute and chronic viral hepatitis, autoimmune hepatitis, complications of advanced liver disease, hepatocellular carcinoma, acute and chronic pancreatitis, inflammatory bowel disease and other acute and chronic bowel diseases, and acute and chronic biliary diseases in a large teaching hospital. These activities have been executed for inpatients with acute diseases of the gastrointestinal tract coming from the emergency department and in outpatients facilities.
 - Country: Italy
5. Employer: Policlinico Gemelli Foundation _ Catholic University of the Sacred Heart, Roma
 - Start date: 012018
 - End date: 122018
 - Position: Senior Consultant, Internal Medicine and Gastroenterology
 - Activities: Hepatologist and gastroenterologist. Diagnosis, treatment and follow_up of patients with acute and chronic viral hepatitis, autoimmune hepatitis, complications of advanced liver disease, hepatocellular carcinoma, acute and chronic pancreatitis, inflammatory bowel disease and other acute and chronic bowel diseases, and acute and chronic biliary diseases in a large teaching hospital. These activities have been executed for inpatients with acute diseases of the gastrointestinal tract coming from the emergency department and in outpatients facilities.
 - Country: Italy
6. Employer: Catholic University of the Sacred Heart _ A. Gemelli Hospital
 - Start date: 102006
 - End date: 062015
 - Position: Consultant, Internal Medicine and Gastroenterology
 - Activities:

Hepatologist. Treatment and follow_up of patients with chronic viral hepatitis, autoimmune hepatitis, complications of advanced liver disease and hepatocellular carcinoma in an outpatient clinic of a large teaching hospital. Inpatients: treatment of patients with severe liver failure waiting for liver transplantation (LT). Post_LT follow_up. Treatment of post_LT HCV recurrence. Emergency treatment of patients with hepatic encephalopathy and bleeding from gastroesophageal varices.
 - Country: Italy
7. Employer: Catholic University of the Sacred Heart _ Gemelli Hospital
 - Start date: 101998
 - End date: 092006
 - Position: Contract Consultant, Internal Medicine
 - Activities:

Hepatologist. Treatment and follow_up of patients with chronic viral hepatitis, autoimmune hepatitis, complications of advanced liver disease and hepatocellular carcinoma in an outpatient clinic of a large teaching hospital. Inpatients: treatment of patients with severe liver failure waiting for liver transplantation (LT). Post_LT follow_up. Treatment of post_LT HCV recurrence. Emergency treatment of patients with hepatic encephalopathy and bleeding from gastroesophageal varices. Emergency room service (up to 2003).
 - Country: Italy
8. Employer: Catholic University of the Sacred Heart _ A. Gemelli Hospital

- Start date: 031986
- End date: 111994
- Position: Assistant with one_year contract _ Internal Medicine
- Activities:

Treatment and follow_up of vascular, heart, liver, kidney, infectious and autoimmune diseases. Emergency room service.

- Country: Italy
9. Employer: Catholic University of the Sacred Heart _ Gemelli Hospital
- Start date: 031986
 - End date: 111994
 - Position: Supply Assistant, Internal Medicine
 - Activities:

Treatment and follow_up of vascular, heart, liver, kidney, infectious and autoimmune diseases. Emergency room service.

- Country: Italy
10. Employer: Catholic University of the Sacred Heart
- Start date: 112011
 - End date:
 - Position: Contract Professor at School of Gastroenterology
 - Activities:

Formal lessons and tutorial.

- Country: Italy
11. Employer: Catholic University of the Sacred Heart
- Start date: 112013
 - End date: 102019
 - Position: Contract Professor, Degree in Medicine and Surgery
 - Activities: Lecturer of Gastroenterology

- Country: Italy
12. Employer: EMA and AIFA
- Start date: 2013
 - End date:
 - Position: External expert
 - Activities: National scientific advice SAN_015_2013 – So.Se.Pharm S.r.l. – Rifaximin Centralized procedure SOVRIAD TMC435 (Simeprevir) EMEA/H/C0002777 Centralized procedure FALDAPREVIR EMEA/H0003720 Centralized procedure EMEA/H/C/4093 (Obethicolic Acid) Centralized procedure EMEA/H/C/005249/0000 (OBETHICOLIC ACID IN NASH) National scientific advice SAN_12_2013 – Abbvie S.r.l. – ABT_450, ABT_267, ABT_333 National scientific advice SAN_015_2013 – So.Se.Pharm S.r.l. – Rifaximin Study protocol evaluation: EudraCT 2013_002263_26, EudraCT 2013_002658!62 EudraCT 2015_001693_18, EudraCT 2015_001925_18, EudraCT 2015_001963_37

- Country: Italy
13. Employer: Catholic University of the Sacred Heart
- Start date: 1986
 - End date: 122018
 - Position: Clinical research activity (please, see attached list of papers)
 - Activities:
 - Country: Italy

Education and training

- Subject: The Global Health Network
 - Start date: 2022
 - End date:
 - Qualification: CH GCP (R2) Certification
 - Organisation:
 - Country: Italy
- Subject:
 - Start date: 092018
 - End date:
 - Qualification: Advanced life support (ALS) certification
 - Organisation:
 - Country:
- Subject: Catholic University of the Sacred Heart
 - Start date: 101992
 - End date:
 - Qualification: Master degree in Liver and Metabolic Diseases
 - Organisation:
 - Country: Italy
- Subject: Catholic University of the Sacred Heart
 - Start date: 071988
 - End date:
 - Qualification: Master Degree in Internal Medicine
 - Organisation:
 - Country: Italy
- Subject: University of Rome
 - Start date: 031983
 - End date:
 - Qualification: Medical degree
 - Organisation:
 - Country: Italy
- Subject: De Merode Institute
 - Start date: 071985
 - End date:
 - Qualification: Baccalaureat
 - Organisation:
 - Country: Italy

Additional information

Publications

- ROSSI L, MARRA L, MILANI A, SICILIANO M. INTERESSAMENTO DI ALCUNI PARAMETRI DI LABORATORIO IN CORSO DI LITIASI BILIARE. IL PATOLOGO CLINICO 1985; 12: 115_118. 2. MILANI A, MARRA L, SICILIANO M,

ROSSI L. PROGNOSTIC SIGNIFICANCE OF CLINICAL AND LABORATORY PARAMETERS IN LIVER CIRRHOSIS. A MULTIVARIATE STATISTICAL APPROACH. HEPATO_GASTROENTEROLOGY 1985; 32: 270_272. 3. ROSSI L, MILANI A, MARRA L, SICILIANO M. CHANGES IN THE PARAMETERS OF HEPATIC FUNCTION IN BILIARY LITHIASIS. QUAD SCLAVO DIAGN 1985; 21: 430_435. 4. ROSSI L, SICILIANO M, BOMBARDIERI G, DE ROSA G, MILANI A. HYPOKALIEMIC SYNDROME DUE TO A PSEUDO_ ALDOSTERONISM SECONDARY TO THE ENDOCONJUNCTIVAL ADMINISTRATION OF A MINERALOACTIVE STEROID. CLIN TER 1986; 117: 147_151. 5. ROSSI L, MILANI A, MARRA L, SICILIANO M. GRADING SCORES AND SURVIVORSHIP FUNCTIONS IN LIVER CIRRHOSIS. A COMPARATIVE STATISTICAL ANALYSIS OF VARIOUS PREDICTIVE MODELS. HEPATO_GASTROENTEROLOGY 1986; 33: 240_243. 6. SICILIANO M, MILANI A, ROSSI L. PROGNOSTIC SIGNIFICANCE OF SERUM BILE ACIDS IN CIRRHOSIS. HEPATOLOGY 1986; 6: 1445. 7. SICILIANO M, MILANI A, MARRA L, ARRINGOLI D, ROSSI L. SERUM BILE ACIDS IN CIRRHOSIS: CORRELATION WITH LIVER FUNCTION PARAMETERS AND WITH THE SEVERITY OF THE DISEASE. QUAD SCAVO DIAGN 1986; 22: 355_361. 8. MILANI A, ROSSI L, MARRA L, SICILIANO M. MODELLO STATISTICO MULTIVARIATO PER LA PREVISIONE DELLA SOPRAVVIVENZA NELLA CIRROSI EPATICA DI VARIA EZIOLOGIA. IL POLICLINICO (SEZ. MEDICA) 1986; 93: 106_110. 9. SICILIANO M, MILANI A, MARRA L, ROSSI L. SERUM BILE ACIDS IN LIVER CIRRHOSIS: PROGNOSTIC SIGNIFICANCE EVINCED BY A MULTIVARIATE STATISTICAL MODEL. ZEITSCHRIFT FÜR GASTROENTEROLOGIE 1987; 25: 721_725. 10. MILANI A, DEGEN C, ROSSI L, LORENZIN F, SICILIANO M. POLYANGIITIS OVERLAP SYNDROME IN CORSO DI COLITE ULCEROSA. IL POLICLINICO (SEZ. MEDICA) 1987; 94: 149_153. 11. MILANI A, MARRA L, SICILIANO M, ROSSI L. CRITICAL STUDY ON THE PREDICTIVE VALUE OF SINGLE LABORATORY PARAMETERS IN HEPATIC CIRRHOSIS. RECENTI PROG MED 1988; 79: 159_163. 12. SICILIANO M, LORENZIN F, MILANI A, ROSSI L. SIGNIFICANCE AND LIMITATIONS OF THE RADIOIMMUNOLOGIC DETERMINATION OF THE AMINOTERMINAL PEPTIDE OF PROCOLLAGEN III IN CHRONIC HEPATOPATHIES. ANN ITAL MED INT 1988; 3: 203_207. 13. LORENZIN F, SICILIANO M, MILANI A, ROSSI L. IL DOSAGGIO DEL PEPTIDE AMINOTERMINALE DEL PROCOLLAGENE DI TIPO III NELLA CIRROSI EPATICA: SIGNIFICATO CLINICO E VALORE PROGNOSTICO. IL POLICLINICO (SEZ. MEDICA) 1988, 95:208_213. 14. MILANI A, MARRA L, SICILIANO M, ROSSI L. LABORATORY PARAMETERS IN THE NATURAL HISTORY OF LIVER CIRRHOSIS. RESEARCH IN CLINIC AND LABORATORY 1989; 19: 173_178. 15. ROSSI L, SICILIANO M, MILANI A, MARRA L, ADAMO EB. ACIDI BILIARI SIERICI NELLA CIRROSI EPATICA: VALORE PROGNOSTICO. ACTI ACCADEMIA PELORITANA DEI PERICOLANTI (CLASSE DI SCIENZE MEDICO_BIOLOGICHE) 1989; 77: 135_143. 16. SICILIANO M, BARBESINO G, MARRA L, MILANI A, ROSSI L. LONG TERM PROGNOSTIC SIGNIFICANCE OF SERUM BILE ACIDS IN LIVER CIRRHOSIS: A PROSPECTIVE STUDY. ZEITSCHRIFT FÜR GASTROENTEROLOGIE 1989; 27: 653_656. 17. LORENZIN F, DEGEN C, MILANI A, SICILIANO M, ROSSI L. PSEUDO_ HYPERALDOSTERONISM CAUSED BY LICORICE. PATHOGENETIC CONSIDERATIONS AND PRESENTATION OF A CLINICAL CASE. CLIN TER 1990; 132: 55_58. 18. SICILIANO M, LORENZIN F, MILANI A, ROSSI L. CLINICAL SIGNIFICANCE OF SERUM BILE ACID DETERMINATION IN LIVER DISEASES. ANN ITAL MED INT 1990; 5: 134_139. 19. MILANI A, CIAMMELLA AM, DEGEN C, SICILIANO M, ROSSI L. ASCITES DYNAMICS IN CIRRHOSIS. PROPOSAL AND VALIDATION OF A METHYLENE BLUE DILUTION TEST. JOURNAL OF HEPATOLOGY 1992; 16: 369_375. 20. SICILIANO M, ROSSI L. CONGESTIVE GASTROPATHY IN LIVER CIRRHOSIS. MINERVA MED 1993; 84: 403_408. 21. SICILIANO M, TOMASELLO D, MILANI A, RICERCA BM, STORTI S, ROSSI L. ERYTHROPOIETIN SECRETION IN LIVER DISEASE. CLIN CHIM ACTA 1995; 236: 217_218. 22. SICILIANO M, TOMASELLO D, MILANI A, RICERCA BM, STORTI S, ROSSI L. REDUCED SERUM LEVELS OF IMMUNOREACTIVE ERYTHROPOIETIN IN PATIENTS WITH LIVER CIRRHOSIS AND CHRONIC ANEMIA. HEPATOLOGY 1995; 22: 1132_1135. 23. CARELLA G, MAZZONE M, BURRAI I, CARBONE L, SICILIANO M. ANTIRODERIVATI: ALCUNE CONSIDERAZIONI SULL'AZIONE ANTIPIASTRINICA. CLIN TER 2000; 151: 345_47. 24. SICILIANO M, DE CANDIA E, BALLARIN S, VECCHIO FM, SERVIDEI S, ANNESE R, LANDOLFI R, ROSSI L. HEPATOCELLULAR CARCINOMA COMPLICATING LIVER CIRRHOSIS IN TYPE IIIA GLYCOGEN STORAGE DISEASE. J CLIN GASTROENTEROL 2000;31:80_82. 25. SICILIANO M, METTIMANO M, DONDOLINI POLI A, BALLARIN S, MIGNECO A, ANNESE R, FAZZARI L, FEDELI P, MONTEBELLIMR, ZUPPI C, SAVI L. TROPONIN I SERUM CONCENTRATION: A NEW MARKER OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION. ITALIAN HEART JOURNAL 2000; 1: 532_535. 26. MAZZONE M, SICILIANO M, CARELLA G. MULTIPLE DICLOFENAC_ INDUCED ADVERSE EFFECTS. AM J GASTROENTEROL 2000; 95: 2988_2989. 27. CARELLA G, MAZZONE M, CARBONE L, SICILIANO M. A CLINICAL CASE OF HEPATIC PSITTACOSIS WITH ULTRASONOGRAPHY ANOMALIES OF THE LIVER. CLIN TER 2001; 152: 201_202. 28. FONTANA T, SICILIANO M, FRANCESCHELLI A, ANNICCHIARICO BE, ROSSI P, BIGOTTI G, BOMBARDIERI G. AN ATYPICAL BONE METASTASIS OF HEPATOCELLULAR CARCINOMA: CASE REPORT AND REVIEW OF THE LITERATURE. CLIN TER 2004; 155: 447_51. 29. ANNICCHIARICO BE, SICILIANO M. PEGYLATED INTERFERON_ ALPHA 2B MONOTHERAPY FOR HAEMODIALYSIS PATIENTS WITH CHRONIC HEPATITIS C. ALIMENT PHARMACOL THER 2004; 20:123_124. 30. ANNICCHIARICO BE, SICILIANO M. COULD IRBESARTAN TRIGGER AUTOIMMUNE CHOLESTATIC HEPATITIS? EUR J GASTROENTEROL HEPATOL 2005; 17: 247_248. 31. SICILIANO M, ANNICCHIARICO BE, FRANCESCHELLI A. ERITHROPOETIN SECRETION IN PATIENTS WITH LIVER CIRRHOSIS. SCAND J GASTROENTEROL 2005; 40: 122_123. 32. SICILIANO M, ANNICCHIARICO BE, LUCCHESI F, BOMBARDIERI G. EFFECTS OF A SINGLE, SHORT INTRAVENOUS DOSE OF ACETYL_ L_ CARNITINE ON PATTERN_ REVERSAL VISUAL_ EVOKED POTENTIALS IN CIRRHOTIC PATIENTS WITH HEPATIC ENCEPHALOPATHY. CLIN EXP PHARMACOL PHYSIOL 2006; 33: 76_80. 33. AVOLIO AW, AGNES S, GASBARRINI A, NURE E, SICILIANO M, POMPILI M, CASTAGNETO M. THE NONSTANDARD LIVER, A HIDDEN RESOURCE THAT CANNOT BE OVERLOOKED: IMPLICATIONS FOR THE IDENTIFICATION OF THE BEST RECIPIENT. TRANSPLANT PROC 2006; 38: 1055_1058. 34. AVOLIO AW, AGNES S, GASBARRINI A, NURE E, SICILIANO M, CASTAGNETO M. PROGNOSTIC VALUE OF MELD SCORE AND DONOR QUALITY IN LIVER TRANSPLANTATION: IMPLICATIONS FOR THE DONOR RECIPIENT MATCH. TRANSPLANT PROC 2006; 38: 1059_1062. 35. DE SIMONE C, PARADISI A, CAPIZZI R, CARBONE A, SICILIANO M, AMERIO PL. ETANERCEPT THERAPY IN TWO PATIENTS WITH PSORIASIS AND CONCOMITANT HEPATITIS C. J AM ACAD DERMATOL 2006; 54: 1102_1005. 36. AVOLIO AW, AGNES S, GASBARRINI A, BARBARINO R, NURE E, SICILIANO M, BARONE M, CASTAGNETO M. ALLOCATION OF NONSTANDARD LIVERS TO TRANSPLANT CANDIDATES WITH HIGH MELD SCORES: SHOULD THIS PRACTICE BE CONTINUED? TRANSPLANT PROC 2006; 38: 3567_71. 37. ANNICCHIARICO BE, SICILIANO M, BOMBARDIERI G. PROXIMAL SPLENIC ARTERY EMBOLIZATION ALLOWS PEGYLATED INTERFERON AND RIBAVIRIN COMBINATION THERAPY IN CHRONIC HEPATITIS C VIRUS INFECTED PATIENTS WITH SEVER CYTOPENIA. EUR J GASTROENTEROL HEPATOL 2006; 18: 119_21. 38. IACOBELLIS A, SICILIANO M, PERRI F, ANNICCHIARICO BE, LEANDRO G, CARUSO N, ACCADIA L, BOMBARDIERI G, ANDRIULLI A. PEGINTERFERON ALFA_2B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS AND DECOMPENSATED CIRRHOSIS: A CONTROLLED STUDY. J HEPATOL 2007; 46: 206_212. 39. ANNICCHIARICO BE, SICILIANO M, GRILLO MR, AVOLIO WA, BOMBARDIERI G. LATE RESOLUTION OF CHRONIC HEPATITIS C AFTER ANTIVIRAL THERAPY. A 5_ YEAR PROSPECTIVE STUDY. ALIMENT PHARMACOL THER 2007; 25: 1039_1046. 40. PASSALACQUA S, AURELI F, GASBARRINI A, BOMBARDIERI G, SICILIANO M, COSTANZI S, FULIGNATI PL, STURNIOLO A, CULLA B, POLA P, RUOLO DEI SISTEMI ARTIFICIALI DI SUPPORTO EXTRACORPOREO NELLA INSUFFICIENZA EPATICA. NOSTRA ESPERIENZA SU 28 PAZIENTI AFFETTI DA EPATOPATIA DI VARIA NATURA E TRATTATI CON PLASMAEXCHANGE E PLASMAPERFUSIONE. TN&D 2007; 1: 31_37. 41. ANNICCHIARICO BE, SICILIANO M, AVOLIO AW, CARACCIOLIO G, GASBARRINI A, AGNES S, CASTAGNETO M. TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON AND RIBAVIRIN IN CIRRHOTIC PATIENTS WAITING FOR LIVER TRANSPLANTATION. TRANSPLANT PROC 2008; 40: 1918_1920. 42. ANNICCHIARICO BE, AVOLIO AW, SICILIANO M, PASSALACQUA S, CARACCIOLIO G, GASBARRINI A, AGNES S, CASTAGNETO M. ACUTE DECOMPENSATION AND ABSENCE OF BRAIN AND KIDNEY DYSFUNCTION PREDICT LONG_ TERM EFFICACY OF PLASMA EXCHANGE IN HYPER_ BILIRUBINEMIC CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION. TRANSPLANT PROC 2008; 40: 1929_1931. 43. AVOLIO AW, BARBARINO R, SICILIANO M, ANNICCHIARICO BE, FRONGILLO F, AGNES S, CASTAGNETO M. DONOR_ RECIPIENT MELD_ BASED MATCH IN A PATIENT WHO REQUIRED THREE LIVER GRAFTS IN THE ERA OF NONSTANDARD DONORS: CASE REPORT. TRANSPLANT PROC 2008; 40: 2067_2069. 44. AVOLIO AW, SICILIANO M, BARBARINO R, NURE E, ANNICCHIARICO BE, GASBARRINI A, AGNES S, CASTAGNETO M. DONOR RISK INDEX AND ORGAN PATIENT INDEX AS PREDICTORS OF GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION. TRANSPLANT PROC 2008; 40: 1899_1902. 45. ANNICCHIARICO BE, AVOLIO AW, SICILIANO M. ORTHOTOPIC LIVER TRANSPLANTATION AFTER SUCCESSFUL TREATMENT WITH ANTI_ CD_20 MONOCLONAL ANTIBODY (RITUXIMAB) FOR SEVERE STEROID_ RESISTANT AUTOIMMUNE HEMOLYTIC ANAEMIA: A CASE REPORT. TRANSPLANT PROC 2009; 41: 1380_1382. 46. ANNICCHIARICO BE, AVOLIO AW, CARACCIOLIO G, BARBARO B, DI STASI C, SICILIANO M. VERY LATE DEVELOPMENT OF SPLENIC ARTERY ANEURYSM AFTER LIVER TRANSPLANTATION. TRANSPLANT PROC 2009; 41: 1383_1385. 47. IACOBELLIS A, SICILIANO M, ANNICCHIARICO BE, VALVANO MR, NIRO GA, ACCADIA L, CARUSO N, BOMBARDIERI G, ANDRIULLI A. SUSTAINED VIROLOGIC RESPONSES FOLLOWING

STANDARD ANTIVIRAL THERAPY IN DECOMPENSATED HCV_INFECTED CIRRHOTIC PATIENTS. ALIMENT PHARMACOL THER 2009; 30: 146_153. 48. PARADISI A, CALDAROLA G, CAPIZZI R, SICILIANO M, ANNICCHIARICO E, VECCHIO FM, AMERIO PL, DE SIMONE C. SAFETY OF ETANERCEPT IN PATIENTS WITH PSORIASIS AND HEPATITIS C VIRUS ASSESSED BY LIVER HISTOPATHOLOGY: PRELIMINARY DATA. J AM ACAD DERMATOL 2010; 62:1067_1069. 49. D'ETTORRE G, BARBARINI G, CORTI F, GOBBER M, PASTECCHIA C, RICCI GL, SICILIANO M, ANNICCHIARICO BE, VULLO V. SEROCONVERSION OF HBSAG IN HBAG POSITIVE AND HBAG NEGATIVE PATIENTS WITH CHRONIC HBV TREATED WITH ENTECAVIR: A CASE SERIES. EUR REV MED PHARMACOL SCI 2010; 14: 551_554. 50. AVOLIO AW, CILLO U, SALIZZONI M, DE CARLIS L, COLLEDAN M, GERUNDA GE, MAZZAFERRO V, TISONE G, ROMAGNOLI R, CACCAMO L, ROSSI M, VITALE A, CUCCHETTI A, LUPO L, GRUTTADAURIA S, NICOLOTTI N, BURRA P, GASBARRINI A, AGNES S; DONOR_TO_RECIPIENT ITALIAN LIVER TRANSPLANT (D2R_ILTX) STUDY GROUP. AM J TRANSPLANT. 2011 ;11):2724_36. 51. ANNICCHIARICO BE, SICILIANO M, GASBARRINI A. CHRONIC HEPATITIS C VIRUS INFECTION: CLINICAL PICTURE AND TREATMENT POSSIBILITIES. G ITAL NEFROL. 2012 JAN_FEB;29 SUPPL 54:S103_8. ITALIAN. 52. IANIRO G, CAMMAROTA G, VALERIO L, ANNICCHIARICO BE, MILANI A, SICILIANO M, GASBARRINI A. MICROSCOPIC COLITIS. WORLD J GASTROENTEROL. 2012 ;18:6206_15. 53. AVOLIO AW, SICILIANO M, BARONE M, LAI Q, CARACCILO GL, BARBARINO R, NICOLOTTI N, LIROSI MC, GASBARRINI A, AGNES S. MODEL FOR END_STAGE LIVER DISEASE DYNAMIC STRATIFICATION OF SURVIVAL BENEFIT. TRANSPLANT PROC. 2012 ;44:1851_6. 54. IEZZI R, CESARIO V, SICILIANI L, CAMPANALE M, DE GAETANO AM, SICILIANO M, AGNES S, GIULIANTE F, GRIECO A, POMPILI M, RAPACCINI GL, GASBARRINI A, BONOMO L; HEPATOCATT GROUP FOR THE MULTIDISCIPLINARY MANAGEMENT OF HCC. SINGLE_STEP MULTIMODAL LOCOREGIONAL TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: BALLOON_OCCLUDED PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION (BO_RFA) PLUS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE). RADIOL MED. 2013 JAN 28. [EPUB AHEAD OF PRINT] 55. PONZIANI FR, ANNICCHIARICO EB, SICILIANO M, D'AVERSA F, POMPILI M, GASBARRINI A. TREATMENT OF HEPATITIS C IN COMPENSATED CIRRHOTIC PATIENTS IS EQUALLY EFFECTIVE BEFORE AND AFTER LIVER TRANSPLANTATION. WORLD J GASTROENTEROL. 2013;19:3255_62 56. ZOCCO MA, GARCOVICH M, LUPASCU A, DI STASIO E, ROCCARINA D, ANNICCHIARICO BE, RICCARDI L, AINORA ME, PONZIANI F, CARACCILO G, RAPACCINI GL, LANDOLFI R, SICILIANO M, POMPILI M, GASBARRINI A. EARLY PREDICTION OF RESPONSE TO SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF DYNAMIC CONTRAST ENHANCED ULTRASOUND. J HEPATOL. 2013 JUN 25. DOI:PII: S0168_8278(13)00427_3. 10.1016/J.JHEP.2013.06.011. [EPUB AHEAD OF PRINT]. 57. GASBARRINI A, PONZIANI FR, ANNICCHIARICO BE, SICILIANO M, CRAXI A. THE NEW ERA OF HEPATITIS C TREATMENT: STILL THE TIP OF THE ICEBERG? EUR REV MED PHARMACOL SCI. 2013 SEP;17(17):2271_4. 58. CUCCHETTI A, TREVISANI F, PECORELLI A, ERROI V, FARINATI F, CICCARESE F, RAPACCINI GL, DI MARCO M, CATURELLI E, GIANNINI EG, ZOLI M, BORZIO F, CABIBBO G...AND ITALIAN LIVER CANCER GROUP. ESTIMATION OF LEAD_TIME BIAS AND ITS IMPACT ON THE OUTCOME OF SURVEILLANCE FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA. J HEPATOL. 2014;61:333_41. doi: 10.1016/j.jhep.2014.03.037. 59. ANNICCHIARICO BE, RICCIONI ME, SICILIANO M, URGESI R, SPADA C, CARACCILO G, GASBARRINI A, COSTAMAGNA G. A PILOT STUDY OF CAPSULE ENDOSCOPY AFTER A STANDARD MEAL FOR THE DETECTION AND GRADING OF OESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS. DIG LIVER DIS; 2014 Sep 2. pii: S1590_8658(14)00647_1. doi: 10.1016/j.dld.2014.08.030. 60. CENTO V, DI PAOLO D, DI CARLO D, MICHELI V, TONTODONATI M, DE LEONARDIS F, ARAGRI M, ANTONUCCI FP, DI MAIO VC, MANCON A, LENCI I, MANUNTA A, TALIANI G, DI BIAGIO A, NICOLINI LA, NOSOTTI L, SARRECCIA C, SICILIANO M, LANDONIO S, PELLICELLI A, GASBARRINI A, VECCHIET J, MAGNI CF, BABUDIARI S, MURA MS, ANDREONI M, PARRUTI G, RIZZARDINI G, ANGELICO M, PERNO CF, CECCHERINI_SILBERSTEIN F. HEPATITIS C VIRUS RNA LEVELS AT WEEK_2 OF TELAPREVIR/BOCEPREVIR ADMINISTRATION ARE PREDICTIVE OF VIROLOGICAL OUTCOME. DIG LIVER DIS. 2015;47:157_63. 61. IEZZI R, POMPILI M, LA TORRE MF, CAMPANALE MC, MONTAGNA M, SAVIANO A, CESARIO V, SICILIANO M, ANNICCHIARICO E, AGNES S, GIULIANTE F, GRIECO A, RAPACCINI GL, DE GAETANO AM, GASBARRINI A, BONOMO L; HEPATOCATT STUDY GROUP FOR THE MULTIDISCIPLINARY MANAGEMENT OF HCC. RADIOFREQUENCY ABLATION PLUS DRUG_ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF SINGLE LARGE HEPATOCELLULAR CARCINOMA. DIG LIVER DIS. 2015;47:242_62. PISCAGLIA F, SVEGLIATI BARONI G, BARCHETTI A, PECORELLI A, MARINELLI S, TIRIBELLI C, BELLENTANI S; HCC_NAFLD ITALIAN STUDY GROUP. CLINICAL PATTERNS OF HEPATOCELLULAR CARCINOMA IN NONALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER PROSPECTIVE STUDY. HEPATOLOGY 2016;63:827_38. 63. HEMOSTATIC BALANCE IN PATIENTS WITH LIVER CIRRHOSIS: REPORT OF A CONSENSUS CONFERENCE. DIG LIVER DIS. 2016;48:455_67. 64. DI MAIO VC, CENTO V, DI PAOLO D, ARAGRI M, DE LEONARDIS F, TONTODONATI M, MICHELI V, BELLOCCHI MC, ANTONUCCI FP, BERTOLI A, LENCI I, MILANA M, GIANSSERRA L, MELIS M, DI BIAGIO A, SARRECCIA C, SARMATI L, LANDONIO S, FRANCIO S, LAMBIASE L, NICOLINI LA, MARENCO S, NOSOTTI L, GIANNELLI V, SICILIANO M, ROMAGNOLI D, PELLICELLI A, VECCHIET J, MAGNI CF, BABUDIARI S, MURA MS, TALIANI G, MASTROIANNI C, VESPASIANI_GENTILUCCI U, ROMANO M, MORISCO F, GASBARRINI A, VULLO V, BRUNO S, BAIGUERA C, PASQUAZZI C, TISONE G, PICCIOTTO A, ANDREONI M, PARRUTI G, RIZZARDINI G, ANGELICO M, PERNO CF, CECCHERINI_SILBERSTEIN F; HCV ITALIAN RESISTANCE NETWORK STUDY GROUP. HCV NS3 SEQUENCING AS A RELIABLE AND CLINICALLY USEFUL TOOL FOR THE ASSESSMENT OF GENOTYPE AND RESISTANCE MUTATIONS FOR CLINICAL SAMPLES WITH DIFFERENT HCV_RNA LEVELS. J ANTIMICROB CHEMOTHER 2016;71:739_50. 65. IEZZI R, POMPILI M, NESTOLA M, SICILIANO M, ANNICCHIARICO E, ZOCCO MA, RINNINELLA E, POSA A, ANTONUCCIO GE, GASBARRINI A, BONOMO L; HEPATOCATT STUDY GROUP.MTRANSARTERIAL CHEMOEMBOLIZATION WITH DEGRADABLE STARCH MICROSPHERES (DSM_TACE): AN ALTERNATIVE OPTION FOR ADVANCED HCC PATIENTS? PRELIMINARY RESULTS. EUR REV MED PHARMACOL SCI. 2016 ;20(:2872_7. 66. GIUGA M, DE GAETANO AM, GUERRA A, INFANTE A, IEZZI R, SPINELLI I, SICILIANO M, GRIECO A, RAPACCINI GL, GASBARRINI A, POMPILI M, BONOMO L. AN UPDATE ON CLINICAL APPLICATIONS OF HEPATOSPECIFIC CONTRAST MEDIA IN MAGNETIC RESONANCE IMAGING OF LIVER PARENCHYMA. EUR REV MED PHARMACOL SCI. 2016;20:2515_25. 66. PELLICELLI AM, PACE PALITTI V, VIGNALLY P, CECCHERINI_SILBERSTAIN F, SICILIANO M, GIANNELLI V, MORETTI A, TARQUINI P, SCIFO G, MESSINA V, ASCIONE A, IZZI A, MARIGNANI M, D'AMBROSIO C, FONDACARO L, ETTORRE GM, IALONGO P, SACCO R, PERNO CF, BARBARINI G; CLEO GROUPEFFICACY AND SAFETY OF SOFOSBUVIR/SIMEPREVIR PLUS FLAT DOSE RIBAVIRIN IN GENOTYPE_1 ELDERLY CIRRHOTIC PATIENTS: A REAL LIFE STUDY. LIVER INT. 2016 OCT 26. 67.. DI MAIO VC, CENTO V, LENCI I, ARAGRI M, ROSSI P, BARBALISCIA S, MELIS M, VERUCCHI G, MAGNI CF, TETI E, BERTOLI A, ANTONUCCI F, BELLOCCHI MC, MICHELI V, MASETTI C, LANDONIO S, FRANCIO S, SANTOPAULO F, PELLICELLI AM, CALVARUSO V, GIANSSERRA L, SICILIANO M, ROMAGNOLI D, COZZOLONGO R, GRIECO A, VECCHIET J, MORISCO F, MERLI M, BRANCACCIO G, DI BIAGIO A, LOGGI E, MASTROIANNI CM, PACE PALITTI V, TARQUINI P, PUOTI M, TALIANI G, SARMATI L, PICCIOTTO A, VULLO V, CAPORASO N, PAOLONI M, PASQUAZZI C, RIZZARDINI G, PARRUTI G, CRAXI A, BABUDIARI S, ANDREONI M, ANGELICO M, PERNO CF, CECCHERINI_SILBERSTEIN F; HCV ITALIAN RESISTANCE NETWORK STUDY GROUP. MULTICLASS HCV RESISTANCE TO DIRECT_ACTING ANTIVIRAL FAILURE IN REAL_LIFE PATIENTS ADVOCATES FOR TAILORED SECOND_LINE THERAPIES.LIVER INT. 2017 JAN 20. DOI: 10.1111/LIV.13327. 68. PONZIANI FR, SICILIANO M, LIONETTI R, PASQUAZZI C, GIANSSERRA L, D'OFFIZI G, GASBARRINI A, POMPILI M. EFFECTIVENESS OF PARITAPREVIR/RITONAVIR/OMBITASVIR/DASABUVIR IN HEMODIALYSIS PATIENTS WITH HEPATITIS C VIRUS INFECTION AND ADVANCED LIVER FIBROSIS: CASE REPORTS. AM J KIDNEY DIS. 2017 MAR 1. PII: S0272_6386(17)30112_9. DOI: 10.1053/J.AJKD.2017.01.037. [EPUB AHEAD OF PRINT] 69. CENTO V, BARBALISCIA S, LENCI I, RUGGIERO T, MAGNI CF, PAOLUCCI S, BABUDIARI S, SICILIANO M, PASQUAZZI C, CIANCIO A, PERNO CF, CECCHERINI_SILBERSTEIN F, ON BEHALF OF HCV RETREATMENT TEAM VIRONET_C STUDY GROUP, MICHELI V, TROSHINA Y, BILIOTTI E, MILANA M, MELIS M, TETI E, LAMBIASE L, MENZAGHI B, NICOLINI LA, MARENCO S, DI MAIO VC, ARAGRI M, PECCHIOLI A, BERTOLI A, SARRECCIA C, MACERA M, COPPOLA N, PUOTI M, ROMAGNOLI D, PELLICELLI A, BONORA S, NOVATI S, BALDANTI F, GHISSETTI V, ANDREONI M, TALIANI G, RIZZARDINI G, ANGELICO M, OPTIMAL EFFICACY OF INTERFERON_FREE HCV RETREATMENT AFTER PROTEASE INHIBITORS FAILURE IN REAL LIFE, CLINICAL MICROBIOLOGY AND INFECTION (2017), DOI:10.1016/J.CMI.2017.04.005. 70. CENTO V, NGUYEN THT, DI CARLO D, BILIOTTI E, GIANSSERRA L, LENCI I, DI PAOLO D, CALVARUSO V, TETI E, CERRONE M, ROMAGNOLI D, MELIS M, DANIELI E, MENZAGHI B, POLILLI E, SICILIANO M, NICOLINI LA, DI BIAGIO A, MAGNI CF, BOLIS M, ANTONUCCI FP, DI MAIO VC, ALFIERI R, SARMATI L, CASALINO P, BERNARDINI S, MICHELI V, RIZZARDINI G, PARRUTI G, QUIRINO T, PUOTI M, BABUDIARI S, D'ARMINIO MONFORTE A, ANDREONI M, CRAXI A, ANGELICO M, PASQUAZZI C, TALIANI G, GUEDJ J, PERNO CF, CECCHERINI_SILBERSTEIN F. IMPROVEMENT OF ALT DECAY KINETICS BY ALL_ORAL HCV TREATMENT: ROLE OF NSSA INHIBITORS AND DIFFERENCES WITH IFN_BASED REGIMENS. PLOS ONE. 2017 MAY 18;12(5):E0177352.

DOI: 10.1371/JOURNAL.PONE.0177352. ECOLLECTION 2017. 71. LORETA A. KONDILI, GIOVANNI BATTISTA GAETA, MAURIZIA ROSSANA BRUNETTO, ALFREDO DI LEO, ANDREA IANNONE, TERESA ANTONIA SANTANTONIO, ADELE GIAMMARIO, GIOVANNI RAIMONDO, ROBERTO FILOMIA, CARMINE COPPOLA, DANIELA CATERINA AMORUSO, PIERLUIGI BLANC, BARBARA DEL PIN, LILIANA CHEMELO, LUISA CAVALLETTO, FILOMENA MORISCO, LAURA DONNARUMMA, MARIA GRAZIA RUMI, ANTONIO GASBARRINI, MASSIMO SICILIANO, MARCO MASSARI, ROMINA CORSINI, BARBARA COCO, SALVATORE MADONIA, MARCO CANNIZZARO, ANNA LINDA ZINIGO, MONICA MONTI, FRANCESCO PAOLO RUSSO, ALBERTO ZANETTO, MARCELLO PERSICO, MARIO MASARONE, ERICA VILLA, VERONICA BERNABUCCI, GLORIA TALIANI, ELISA BILIOTTI, LUCHINO CHESSA, MARIA CRISTINA PASETTO, PIETRO ANDREONE, MARZIA MARGOTTI, GIUSEPPINA BRANCACCIO, DONATELLA IELUZZI, GUGLIELMO BORGIA, EMANUELA ZAPPULO, VINCENZA CALVARUSO, SALVATORE PETTA, LOREDANA FALZANO, MARIA GIOVANNA QUARANTA, LILIANA ELENA WEIMER, STEFANO ROSATO, STEFANO VELLA, EDOARDO GIOVANNI GIANNINI. INCIDENCE OF DAA FAILURE AND THE CLINICAL IMPACT OF RETREATMENT IN REAL LIFE PATIENTS TREATED IN THE ADVANCED STAGE OF LIVER DISEASE: INTERIM EVALUATIONS FROM THE PITER NETWORK. PUBLISHED 04 OCT 2017 PLOS ONE [HTTPS://DOI.ORG/10.1371/JOURNAL.PONE.0185728](https://doi.org/10.1371/journal.pone.0185728). 72) PONZIANI FR, MANGIOLA F, BINDA C, ZOCCO MA, SICILIANO M, GRIECO A, RAPACCINI GL, POMPILI M, GASBARRINI A. FUTURE OF LIVER DISEASE IN THE ERA OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. *WORLD J HEPATOL*. 2017;9:352-367. 73) BINDA C, TORTORA A, GARCOVICH M, ANNICCHIARICO BE, SICILIANO M. TOXICITY AND RISKS FROM DRUG-TO-DRUG INTERACTIONS OF NEW ANTIVIRALS FOR CHRONIC HEPATITIS C. *EUR REV MED PHARMACOL SCI* 2017;21:102-111. 74) SAVIANO A, IEZZI R, GIULIANTE F, SALVATORE L, MELE C, POSA A, ARDITO F, DE GAETANO AM, POMPILI M; HEPATOCATT STUDY GROUP. LIVER RESECTION VERSUS RADIOFREQUENCY ABLATION PLUS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN CIRRHOTIC PATIENTS WITH SOLITARY LARGE HEPATOCELLULAR CARCINOMA. *J VASC INTERV RADIOL* 2017;28:1512-1519. 75) PONZIANI FR, IRENE SPINELLI, RINNINELLA E, CERRITO L, SAVIANO A, AVOLIO AW, BASSO M, MIELE L, RICCARDI L, ZOCCO MA, ANNICCHIARICO BE, GARCOVICH M, BIOLATO M, MARRONE G, DE GAETANO AM, IEZZI R, GIULIANTE F, GUGLIELMO BORGIA, EMANUELA ZAPPULO, VINCENZA CALVARUSO, SALVATORE PETTA, LOREDANA FALZANO, MARIA GIOVANNA QUARANTA, LILIANA ELENA WEIMER, STEFANO ROSATO, STEFANO VELLA, EDOARDO GIOVANNI GIANNINI. INCIDENCE OF DAA FAILURE AND THE CLINICAL IMPACT OF RETREATMENT IN REAL LIFE PATIENTS TREATED IN THE ADVANCED STAGE OF LIVER DISEASE: INTERIM EVALUATIONS FROM THE PITER NETWORK. PUBLISHED 04 OCT 2017 PLOS ONE [HTTPS://DOI.ORG/10.1371/JOURNAL.PONE.0185728](https://doi.org/10.1371/journal.pone.0185728). 76) LANINI S, SCOGNAMIGLIO P, MECOZZI A, LOMBARDOZZI L, VULLO V, ANGELICO M, GASBARRINI A, TALIANI G, ATTILI AF, PERNO CF, DE SANTIS A, PURO V, CERQUA F, D'OFFIZI G, PELLICELLI AM, MENNINI FS, SICILIANO M, GIRARDI E, PANELLA V, IPPOLITO G; MEMBERS OF THE LAZIO REGION HCV TREATMENT GROUP. IMPACT OF NEW DAA THERAPY ON REAL CLINICAL PRACTICE: A MULTICENTER REGION-WIDE COHORT STUDY. *BMC INFECT DIS* 2018;18:223. 77) BERTOLI A, SORBO MC, ARAGRI M, LENCI I, TETI E, POLILLI E, DI MAIO VC, GIANSSERA L, BILIOTTI E, MASETTI C, MAGNI CF, BABUDIERI S, NICOLINI LA, MILANA M, CACCIATORE P, SARMATI L, PELLICELLI A, PAOLUCCI S, CRAXI A, MORISCO F, PALITTI VP, SICILIANO M, COPPOLA N, IAPADRE N, PUOTI M, RIZZARDINI G, TALIANI G, PASQUAZZI C, ANDREONI M, PARRUTI G, ANGELICO M, PERNO CF, CENZO V, CECCHERINISILBERSTEIN F. PREVALENCE OF SINGLE AND MULTIPLE NATURAL NS3, NS5A AND NS5B RESISTANCE ASSOCIATED SUBSTITUTIONS IN HEPATITIS C VIRUS GENOTYPES 1-4 IN ITALY. *SCI REP* 2018;8:8988. 78) VASSALLO GA, TARLI C, RANDO MM, MOSONI C, MIRIJELLO A, AGYEI-NKANSAH A, ANTONELLI M, SESTITO L, PEROTTI G, DI GIUDA D, AGNES S, GRIECO A, GASBARRINI A, ADDOLORATO G; GEMELLI OLT GROUP. LIVER TRANSPLANTATION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A RETROSPECTIVE STUDY. *ALCOHOL* 2018;53:151-156. 79) CERRITO L, PONZIANI FR, GARCOVICH M, TORTORA A, ANNICCHIARICO BE, POMPILI M, SICILIANO M, GASBARRINI A. REGORAFENIB: A PROMISING TREATMENT FOR HEPATOCELLULAR CARCINOMA. EXPERT OPIN PHARMACOTHER. 2018;20:1-8. 80) MASETTI C, LIONETTI R, LUPO M, SICILIANO M, GIANNELLI V, PONZIANI FR, TETI E, DELL'UNTO C, FRANCIOSI S, BREGA A, MONTALBANO M, VISCO-COMANDINI U, TAIBI C, GALATI G, VESPASIANI GENTILUCCI U, PICARDI A, ANDREONI M, POMPILI M, PELLICELLI AM, D'OFFIZI G, GASBARRINI A, DE SANTIS A, ANGELICO M. LACK OF REDUCTION OF SERUM ALPHAFETOPROTEIN DURING TREATMENT WITH DIRECT ANTIVIRAL AGENTS PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A LARGE COHORT OF PATIENTS WITH HCV-RELATED CIRRHOSIS. *J VIRAL HEPAT*. 2018;25:1493-1500. 81) IEZZI R, POMPILI M, RINNINELLA E, ANNICCHIARICO BE, GARCOVICH M, CERRITO L, PONZIANI F, DE GAETANO A, SICILIANO M, BASSO M, ZOCCO MA, RAPACCINI G, POSA A, CARCHESIO F, BIOLATO M, GIULIANTE F, GASBARRINI A, MANFREDI R; HEPATOCATT STUDY GROUP. TACE WITH DEGRADABLE STARCH MICROSPHERES (DSM-TACE) AS SECOND-LINE TREATMENT IN HCC PATIENTS DISMISSING OR INELIGIBLE FOR SORAFENIB. *EUR RADIOL*. 2019;29:1285-1292. 82) ANNICCHIARICO BE, SANTONOCITO, SICILIANO M, SCAPATICCI M, GUARINO D, DI STASI C, RICCIONI ME DI STASIO E, CAPOLUONGO E, GASBARRINI A. ACE I ALLELE IS ASSOCIATED WITH MORE SEVERE PORTAL HYPERTENSION IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT STUDY. *DIG LIVER DIS* 2019;51:293-296. 83) IEZZI R, POMPILI M, POSA A, CARCHESIO F, SICILIANO M, ANNICCHIARICO BE, AGNES S, GIULIANTE F, GARCOVICH M, CERRITO L, PONZIANI FR, BASSO M, CASSANO A, RAPACCINI GL, DE GAETANO AM, GASBARRINI A, MANFREDI R; HEPATOCATT STUDY GROUP FOR THE MULTIDISCIPLINARY MANAGEMENT OF HCC. INTERVENTIONAL ONCOLOGY TREATMENTS FOR UNRESECTABLE EARLY STAGE HCC IN PATIENTS WITH A HIGH RISK FOR INTRAPROCEDURAL BLEEDING: IS A SINGLE-STEP COMBINED THERAPY SAFE AND FEASIBLE? *EUR J RADIOL*. 2019;114:32-37. 84) LIONETTI R, PICCOLO P, LENCI I, SICILIANO M, VISCO-COMANDINI U, DE SANTIS A, POMPILI M, MILANA M, TAIBI C, DELL'ISOLA S, MONTALBANO M, MASTROIANNI C, BEGINI P, GARBUGLIA AR, ANGELICO M, D'OFFIZI G. DACLATASVIR, SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR 24 WEEKS IN HEPATITIS C GENOTYPE 3 CIRRHOSIS: A REAL-LIFE STUDY. *ANNALS OF HEPATOLOGY* 2019;18:434-438. 85) AINORA ME, IEZZI R, PONZIANI FR, GARCOVICH M, DI STASIO E, RICCARDI L, ANNICCHIARICO BE, ABBATE V, DE GAETANO AM, SICILIANO M, GRIECO A, RAPACCINI GL, GASBARRINI A, POMPILI M, ZOCCO MA. CONTRAST-ENHANCED ULTRASOUND IN THE SHORT-TERM EVALUATION OF HEPATOCELLULAR CARCINOMA AFTER LOCOREGIONAL TREATMENT. 2020 FEB 13 [ONLINE AHEAD OF PRINT] DOI: 10.1159/000506455. 86) PONZIANI FR, SANTO PAOLO F, SICILIANO M, DE BELVIS AG, TORTORA A, MORA V, FANALI C, MORSELLA A, BALDUCCI F, VETRUGNO G, D'ALFONSO ME, CAMBIERI A, CAUDA R, BELLANTONE R, SANGUINETTI M, POMPILI M, GASBARRINI A. MISSED LINKAGE TO CARE FOR PATIENTS WHO SCREENED POSITIVE FOR HEPATITIS C IN A TERTIARY CARE CENTRE: RESULTS OF THE TELEPASS PROJECT. *J VIRAL HEPAT* 2021 APR;28(4):651-656. DOI: 10.1111/JVH.13465. EPUB 2021 JAN 24.

Projects

Memberships

Other Relevant Information

The Forum for Collaborative Research (Berkeley) – Liver Forum Participant